SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis

NASDAQ:SRTS • US81728J1097

4.11 USD
+0.09 (+2.24%)
At close: Feb 27, 2026
4.11 USD
0 (0%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SRTS. SRTS was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While SRTS has a great health rating, there are worries on its profitability. SRTS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SRTS has reported negative net income.
  • SRTS had a positive operating cash flow in the past year.
  • Of the past 5 years SRTS 4 years were profitable.
  • In the past 5 years SRTS always reported negative operating cash flow.
SRTS Yearly Net Income VS EBIT VS OCF VS FCFSRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • SRTS's Return On Assets of -5.16% is fine compared to the rest of the industry. SRTS outperforms 66.49% of its industry peers.
  • SRTS's Return On Equity of -5.87% is fine compared to the rest of the industry. SRTS outperforms 69.73% of its industry peers.
Industry RankSector Rank
ROA -5.16%
ROE -5.87%
ROIC N/A
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRTS Yearly ROA, ROE, ROICSRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • In the last couple of years the Profit Margin of SRTS has remained more or less at the same level.
  • In the last couple of years the Operating Margin of SRTS has grown nicely.
  • SRTS has a Gross Margin of 47.95%. This is comparable to the rest of the industry: SRTS outperforms 42.16% of its industry peers.
  • SRTS's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.95%
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
SRTS Yearly Profit, Operating, Gross MarginsSRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • SRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SRTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRTS Yearly Shares OutstandingSRTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SRTS Yearly Total Debt VS Total AssetsSRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • SRTS has an Altman-Z score of 7.12. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
  • SRTS's Altman-Z score of 7.12 is amongst the best of the industry. SRTS outperforms 84.86% of its industry peers.
  • There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.12
ROIC/WACCN/A
WACC9.88%
SRTS Yearly LT Debt VS Equity VS FCFSRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • SRTS has a Current Ratio of 7.38. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
  • SRTS has a better Current ratio (7.38) than 87.57% of its industry peers.
  • SRTS has a Quick Ratio of 5.27. This indicates that SRTS is financially healthy and has no problem in meeting its short term obligations.
  • SRTS's Quick ratio of 5.27 is amongst the best of the industry. SRTS outperforms 82.16% of its industry peers.
Industry RankSector Rank
Current Ratio 7.38
Quick Ratio 5.27
SRTS Yearly Current Assets VS Current LiabilitesSRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for SRTS have decreased strongly by -217.50% in the last year.
EPS 1Y (TTM)-217.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-311.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.2%

3.2 Future

  • SRTS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.86% yearly.
  • SRTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.94% yearly.
EPS Next Y86.98%
EPS Next 2Y51.43%
EPS Next 3Y48.59%
EPS Next 5Y29.86%
Revenue Next Year15.07%
Revenue Next 2Y23.25%
Revenue Next 3Y30.28%
Revenue Next 5Y23.94%

3.3 Evolution

SRTS Yearly Revenue VS EstimatesSRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SRTS Yearly EPS VS EstimatesSRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • SRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTS Price Earnings VS Forward Price EarningsSRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, SRTS is valued a bit cheaper than the industry average as 78.92% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 31.16
EV/EBITDA N/A
SRTS Per share dataSRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SRTS's earnings are expected to grow with 48.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.43%
EPS Next 3Y48.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SRTS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SENSUS HEALTHCARE INC

NASDAQ:SRTS (2/27/2026, 8:00:00 PM)

After market: 4.11 0 (0%)

4.11

+0.09 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)05-13
Inst Owners29.14%
Inst Owner Change-2.84%
Ins Owners17.9%
Ins Owner Change1.57%
Market Cap67.53M
Revenue(TTM)N/A
Net Income(TTM)-3.01M
Analysts82.22
Price Target6.8 (65.45%)
Short Float %4.31%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-144.08%
Min EPS beat(2)-326.24%
Max EPS beat(2)38.08%
EPS beat(4)1
Avg EPS beat(4)-219.59%
Min EPS beat(4)-561.36%
Max EPS beat(4)38.08%
EPS beat(8)5
Avg EPS beat(8)85.83%
EPS beat(12)6
Avg EPS beat(12)12.6%
EPS beat(16)8
Avg EPS beat(16)15.03%
Revenue beat(2)1
Avg Revenue beat(2)-7.99%
Min Revenue beat(2)-22.89%
Max Revenue beat(2)6.91%
Revenue beat(4)3
Avg Revenue beat(4)3.8%
Min Revenue beat(4)-22.89%
Max Revenue beat(4)18.13%
Revenue beat(8)7
Avg Revenue beat(8)32.09%
Revenue beat(12)7
Avg Revenue beat(12)12.6%
Revenue beat(16)10
Avg Revenue beat(16)14.6%
PT rev (1m)-9.09%
PT rev (3m)-9.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.9
P/FCF 31.16
P/OCF 35.39
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)0.13
FCFY3.21%
OCF(TTM)0.12
OCFY2.83%
SpS2.17
BVpS3.12
TBVpS3.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.16%
ROE -5.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.95%
FCFM 6.09%
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 115.63%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.38
Quick Ratio 5.27
Altman-Z 7.12
F-Score4
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)82.92%
Cap/Depr(5y)64.01%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-217.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-311.11%
EPS Next Y86.98%
EPS Next 2Y51.43%
EPS Next 3Y48.59%
EPS Next 5Y29.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.2%
Revenue Next Year15.07%
Revenue Next 2Y23.25%
Revenue Next 3Y30.28%
Revenue Next 5Y23.94%
EBIT growth 1Y-145.49%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-196.25%
EBIT Next 3Y-15.65%
EBIT Next 5Y-27.34%
FCF growth 1Y114.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.79%
OCF growth 3YN/A
OCF growth 5YN/A

SENSUS HEALTHCARE INC / SRTS FAQ

What is the ChartMill fundamental rating of SENSUS HEALTHCARE INC (SRTS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to SRTS.


What is the valuation status of SENSUS HEALTHCARE INC (SRTS) stock?

ChartMill assigns a valuation rating of 2 / 10 to SENSUS HEALTHCARE INC (SRTS). This can be considered as Overvalued.


What is the profitability of SRTS stock?

SENSUS HEALTHCARE INC (SRTS) has a profitability rating of 3 / 10.


How financially healthy is SENSUS HEALTHCARE INC?

The financial health rating of SENSUS HEALTHCARE INC (SRTS) is 8 / 10.